1stOncology™: Cancer Intelligence Service – Page 14340 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Zymeworks to Present at Upcoming Investor Conferences

On November 7, 2018 Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England (Press release, Zymeworks, NOV 7, 2018, View Source [SID1234530951]).

The Company will provide a corporate update at the Stifel Healthcare Conference on Tuesday, November 13, 2018 at 8:00 a.m. ET and at the Jefferies Healthcare Conference on Wednesday, November 14, 2018 at 2:40 p.m. GMT (9:40 a.m. ET).

Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at View Source, which will also host a recorded replay available afterwards.

Synlogic Announces Third Quarter 2018 Conference Call and Webcast

On November 7, 2018 Synlogic, Inc. (Nasdaq: SYBX), reported that the Company will release its third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018 (Press release, Synlogic, NOV 7, 2018, View Source [SID1234530949]). The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. The conference ID number for the call is 2674209. Participants may access the live webcast via a link on the Synlogic website in the Events Calendar of the Investors and Media section

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

On November 7, 2018 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:10 a.m. MST (8:10 a.m. PST, 11:10 a.m. EST) on Wednesday, November 14, at the Credit Suisse 27th Annual Healthcare Conference (Press release, Puma Biotechnology, NOV 7, 2018, View Source [SID1234530948]). The conference will be held at The Phoenician Resort in Scottsdale, Arizona.

A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference

On November 7, 2018 Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, reported its broad viral vector expertise and their potential to transform the fight against cancer at the annual meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) to be held November 7-11 in Washington DC (USA) (Press release, Transgene, NOV 7, 2018, View Source [SID1234530947]).

myvacTM

Transgene presents first preclinical and translational data supporting its novel myvac platform in a poster entitled:

"Viral based vaccine for personalized neoantigen-directed cancer therapies" (#P148)

Transgene has set up a process aimed at developing a Modified Vaccinia Virus Ankara (MVA)-based, individualized immunotherapy product that recognizes and destroys tumors using their own cancer specific genetic fingerprint.
The immunogenicity of the individualized vaccine has been demonstrated in a humanized mice model.
The immune response observed in the mice model partly overlaps with the one observed in humans, suggesting it can be predicted with the use of an advanced artificial intelligence (AI) approach.
___________________

Invir.IOTM

Transgene and BioInvent are presenting two posters that support their collaboration to develop a novel oncolytic virus encoding for an anti-CTLA-4 antibody:

"Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment" (#P615)

"Generation and characterization of a CTLA-4 antibody with improved FcγR-dependent Treg deletion for tumor microenvironment-targeted oncolytic virotherapy of cancer" (#P602)

More details are available in the press release distributed simultaneously and available on www.transgene.fr.

___________________

Pseudocowpox virus (PCPV)

Transgene will also present a poster on PCPV, the most promising therapeutic candidate amongst the poxviridae recently evaluated by the Company, which could be used as either a single agent or in combination with other viral vectors:

"Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy" (#P181)

Intratumoral administration of PCPV induces tumor-specific T cell responses, reduces tumor size and increases survival in both tumor antigen -dependent and -independent mice models.
PCPV encoding for the HPV-16 E7 antigen induces a strong cellular response against this antigen.
Combining two complementary vectors such as MVA and PCPV is an efficient way to improve tumor growth control.
The four posters will be on display Friday, November 9 and Saturday, November 10 in the Poster Hall (Hall E).